This well-done study should prompt oncologists to consider adding trastuzumab to carboplatin-paclitaxel treatment for women with advanced HER2/neu-positive uterine cancer, says Dr Maurie Markman.
Medscape Oncology
Original Article: Trastuzumab Increases PFS in Women With HER2/neu Uterine Cancer